FDA Approved a New Cholesterol Pill: What to Know

If you manage high cholesterol, you’ve probably heard the news by now. The FDA just approved a new cholesterol pill called Lipfendra (enlicitide), and it’s the first of its kind. Unlike every other drug in its class, which requires injections, this one comes as a simple daily pill. That’s a big deal for anyone who’s ever dreaded needles or struggled with statin side effects.

But here’s the thing. Cardiologists are excited about this new cholesterol pill, but they’re also cautious. And there’s one crucial question that doesn’t have an answer yet: Does it actually prevent heart attacks? Let’s break down what we know, what we don’t know, and what you should ask your doctor.

What Is This New Cholesterol Pill and How Does It Work?

Let’s start with the basics. Lipfendra is the brand name for enlicitide, a drug developed by Merck. It’s what doctors call an oral PCSK9 inhibitor. That mouthful of a name actually describes exactly how it works.

Your liver is responsible for removing LDL cholesterol from your blood. It does this using tiny receptors on its surface that act like grabbers. They reach out, snatch LDL particles, and pull them out of circulation. Normally, after a receptor does its job, it gets recycled and used again. But a protein called PCSK9 interferes with this process. When PCSK9 attaches to an LDL receptor, the receptor gets destroyed instead of recycled. Fewer receptors mean less LDL gets cleared from your blood.

Lipfendra blocks PCSK9. As cardiologist Elizabeth Klodas, M.D., FACC, explains it: “Inhibit PCSK9 and save more LDL receptors — and get lower LDL levels.” It’s that simple. The FDA announced the approval of Lipfendra on July 17, 2026, calling it the first oral PCSK9 inhibitor to reach the market.

What the Research Actually Shows About This New Cholesterol Pill

The data behind Lipfendra is solid — as far as it goes. Two major Phase 3 trials published in top medical journals provide the evidence.

The CORALreef Lipids trial, published in the New England Journal of Medicine, enrolled nearly 2,900 adults with high cholesterol who were already on the highest statin dose they could tolerate. After 24 weeks, those taking enlicitide saw their LDL drop by 57%, while the placebo group actually saw a 3% increase. That’s a difference of nearly 60 percentage points. The results held up at 52 weeks.

The CORALreef HeFH trial, published in JAMA, focused on people with an inherited form of high cholesterol called familial hypercholesterolemia. These 303 participants saw a 58% reduction in LDL at 24 weeks. Notably, 51% of participants in this trial were women.

A third study in the Journal of the American College of Cardiology compared enlicitide head-to-head against other oral nonstatin drugs. The results were striking: enlicitide lowered LDL by 64.6%, compared to just 6.3% for bempedoic acid, 27.8% for ezetimibe, and 36.5% for the combination of both. That’s a dramatic difference.

How This New Cholesterol Pill Compares to Statins and Other Drugs

This is where things get interesting — and where you need the full picture.

Statins work by reducing how much cholesterol your liver produces. Lipfendra works by helping your liver remove more cholesterol from your blood. They target different pathways, which means they can be used together. In fact, most participants in the clinical trials were already taking statins, so the results reflect what happens when you add Lipfendra on top of statin therapy.

The big difference? Statins have decades of research showing they reduce the risk of heart attacks, strokes, and cardiovascular death. Lipfendra does not have that evidence yet. As cardiologist Gregory Katz, M.D., puts it: “Importantly, enlicitide hasn’t been studied in a way that we have certainty about whether it lowers the risk of heart attack, stroke or death.”

That’s not to say Lipfendra won’t eventually show those benefits. The CORALreef Outcomes trial is currently enrolling over 14,500 participants to answer exactly that question. But results won’t be available for a few years. For a closer look at what makes this new cholesterol pill different, read our complete guide.

Who Should Consider This New Cholesterol Pill?

Cardiologists are clear that Lipfendra isn’t for everyone — at least not yet. Here’s who might benefit most:

People who can’t tolerate statins. Statin-related muscle pain is real, and it affects some people significantly. If you’ve tried multiple statins and couldn’t tolerate them, Lipfendra offers a potent alternative that works through a completely different mechanism.

People who need more LDL lowering than statins alone provide. Even on the highest tolerated statin dose, some people still have elevated LDL. Adding Lipfendra could bring those numbers down significantly.

People who prefer pills over injections. Injectable PCSK9 inhibitors are highly effective, but many people are hesitant to start because they don’t want to give themselves shots. As cardiologist Yu-Ming Ni, M.D., told Healthline: “I have a lot of people who are hesitant to even start because they don’t want to give themselves injections.”

People with familial hypercholesterolemia. This inherited condition often requires aggressive LDL lowering beyond what statins alone can achieve. The HeFH trial showed Lipfendra works well in this population.

But here’s the honest truth from cardiologists: If your current cholesterol medication is working well and you’re not experiencing side effects, there may be little reason to switch. As Dr. Katz says: “I’m not ready to switch anyone to this medicine until we have data on longer term results.”

Safety, Side Effects, and What to Know Before Taking It

In clinical trials, Lipfendra was generally well-tolerated. Side effects occurred at similar rates to placebo in the main CORALreef Lipids trial. In the HeFH trial, the most common side effects were diarrhea (7% vs 2% with placebo) and dizziness (9% vs 4%). A systematic review of oral PCSK9 inhibitors confirmed that the safety profile is similar to placebo, with the main exception being a higher risk of diarrhea.

A few practical things to know: Lipfendra should be taken on an empty stomach with water, black coffee, or plain tea. You need to wait at least 30 minutes before eating or drinking anything else. Swallow the tablet whole — don’t crush or chew it.

If you’re pregnant, planning to become pregnant, or breastfeeding, talk to your doctor. The prescribing information includes precautions for these situations.

The Bottom Line: Lifestyle Still Comes First

Here’s what every cardiologist I’ve read agrees on: medications are powerful tools, but they work best alongside a healthy lifestyle. The FDA approved Lipfendra specifically as an “adjunct to diet and exercise” — meaning it’s meant to be used with, not instead of, healthy habits.

What does that look like in practice? Aim for at least 150 minutes of moderate activity each week. Prioritize quality sleep — it supports heart health in ways we’re still discovering. Find ways to manage stress, whether that’s through walking, deep breathing, or simply taking a few minutes for yourself each day.

And yes, what you eat matters. A heart-healthy eating pattern rich in fiber, healthy fats, and whole foods can naturally support healthy cholesterol levels. Think oats, nuts, olive oil, fatty fish, and plenty of vegetables.

The arrival of this new cholesterol pill is genuinely exciting. It offers a potent new option for people who need it. But the smartest approach is to view it as one tool in a larger toolkit — not a magic bullet. Talk to your doctor, ask the right questions, and keep building those healthy habits that support your heart every single day.